Blueprint Medicines Corp (NASDAQ:BPMC) shares, rose in value on Friday, November 01, with the stock price up by 3.65% to the previous day’s close as strong demand from buyers drove the stock to $90.70.
Actively observing the price movement in the last trading, the stock closed the session at $87.51, falling within a range of $87.28 and $90.85. The value of beta (5-year monthly) was 0.578. Referring to stock’s 52-week performance, its high was $121.90, and the low was $56.74. On the whole, BPMC has fluctuated by 2.99% over the past month.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
With the market capitalization of Blueprint Medicines Corp currently standing at about $5.76 billion, investors are eagerly awaiting this quarter’s results, scheduled for on 2025-Feb-13.
Projections by analysts suggest varying estimates for the company’s quarterly revenue. Analysts have estimated the company’s revenue for the quarter at 508.85M, with a low estimate of 141M and a high estimate of 170M. Wall Street analysts also predicted that the company’s y-o-y revenues would reach 146.6M.
Technical indicators serve as essential tools for traders, offering insights into market sentiment and potential price movements. We see that BPMC’s technical picture suggests that short-term indicators denote the stock is a 50% Sell on average. However, medium-term indicators have put the stock in the category of 50% Sell while long-term indicators on average have been pointing out that it is a 50% Sell.
The stock’s technical analysis shows that the price of BPMC currently trading nearly 4.55% and 2.18% away from the simple moving averages for 20 and 50 days respectively. The Relative Strength Index (RSI, 14) currently indicates a reading of 57.73, while the 7-day volatility ratio is showing 4.16% which for the 30-day chart, stands at 3.16%. Furthermore, Blueprint Medicines Corp (BPMC)’s beta value is 0.59, and its average true range (ATR) is 3.33.
A comparison of Blueprint Medicines Corp (BPMC) with its peers suggests the former has fared considerably weaker in the market. BPMC showed an intraday change of 3.65% in last session, and over the past year, it grew by 51.42%%.
Data on historical trading for Blueprint Medicines Corp (NASDAQ:BPMC) indicates that the trading volumes over the past 10 days have averaged 0.81 and over the past 3 months, they’ve averaged 679.09K. According to company’s latest data on outstanding shares, there are 63.53 million shares outstanding.
Nearly 1.82% of Blueprint Medicines Corp’s shares belong to company insiders and institutional investors own 105.14% of the company’s shares. The data on short interest also indicates that stock shorts accounted for 3.62 million shares as on 2024-10-15, resulting in a short ratio of 6.15. According to the data, the short interest in Blueprint Medicines Corp (BPMC) stood at 644.00 of shares outstanding as of 2024-10-15; the number of short shares registered in 2024-09-13 reached 3.67 million. The stock has fallen by -1.67% since the beginning of the year, thereby showing the potential of a further growth. This could raise investors’ confidence to be optimistic about the BPMC stock heading into the next quarter.
